Serum and urinary biochemical markers for knee and hip-osteoarthritis: A systematic review applying the consensus BIPED criteria

Osteoarthritis and Cartilage

Volumn 18, Issue 5, 2010, Pages 605-612

  van Spil, W E ^a   DeGroot, J ^b   Lems, W F ^c   Oostveen, J C M ^d   Lafeber, F P J G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b TNO   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d TWENTEBORG HOSPITAL   (Netherlands)

Author keywords

Biochemical markers; Biomarkers; BIPED classification; Blood; Hip; Knee; Osteoarthritis; Urine

Indexed keywords

BONE SIALOPROTEIN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CHONDROITIN SULFATE; COLLAGEN TYPE 1; COLLAGEN TYPE 2; DEOXYPYRIDINOLINE; HYALURONIC ACID; KERATAN SULFATE; OSTEOCALCIN; PENTOSIDINE; PYRIDINOLINE; RISEDRONIC ACID;

BLOOD ANALYSIS; BONE METABOLISM; CARTILAGE DEGENERATION; COLLAGEN SYNTHESIS; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; HIP OSTEOARTHRITIS; HUMAN; KNEE OSTEOARTHRITIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SYNOVIUM; SYSTEMATIC REVIEW; TREATMENT RESPONSE; URINALYSIS;

BIOLOGICAL MARKERS; BONE AND BONES; CARTILAGE, ARTICULAR; COST OF ILLNESS; HUMANS; OSTEOARTHRITIS, HIP; OSTEOARTHRITIS, KNEE; PROGNOSIS; SYNOVIAL MEMBRANE;

EID: 77952545238     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2010.01.012     Document Type: Review

References (35)

1. Boegard T., Rudling O., Petersson I.F., Jonsson K. Correlation between radiographically diagnosed osteophytes and magnetic resonance detected cartilage defects in the patellofemoral joint. Ann Rheum Dis 1998, 57:395-400.
2. Cicuttini F., Ding C., Wluka A., Davis S., Ebeling P.R., Jones G. Association of cartilage defects with loss of knee cartilage in healthy, middle-age adults: a prospective study. Arthritis Rheum 2005, 52:2033-2039.
3. Cibere J., Zhang H., Garnero P., Poole A.R., Lobanok T., Saxne T., et al. Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. Arthritis Rheum 2009, 60:1372-1380.
4. Wakitani S., Nawata M., Kawaguchi A., Okabe T., Takaoka K., Tsuchiya T., et al. Serum keratan sulfate is a promising marker of early articular cartilage breakdown. Rheumatology (Oxford) 2007, 46:1652-1656.
5. Wagner J.A., Williams S.A., Webster C.J. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharm Ther 2007, 81:104-107.
6. Felson D.T., Lohmander L.S. Whither osteoarthritis biomarkers?. Osteoarthritis Cartilage 2009, 17:419-422.
7. Bauer D.C., Hunter D.J., Abramson S.B., Attur M., Corr M., Felson D., et al. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthritis Cartilage 2006, 14:723-727.
8. Garnero P., Rousseau J.C., Delmas P.D. Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum 2000, 43:953-968.
9. Gineyts E., Garnero P., Delmas P.D. Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation. Rheumatology (Oxford) 2001, 40:315-323.
10. Deberg M., Labasse A., Christgau S., Cloos P., Bang Hendriksen D., Chapelle J.P., et al. New serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 2005, 13:258-265.
11. Downs J.T., Lane C.L., Nestor N.B., McLellan T.J., Kelly M.A., Karam G.A., et al. Analysis of collagenase-cleavage of type II collagen using a neoepitope ELISA. J Immunol Methods 2001, 247:25-34.
12. Charni N., Juillet F., Garnero P. Urinary type II collagen helical peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 2005, 52:1081-1090.
13. Nemirovskiy O.V., Dufield D.R., Sunyer T., Aggarwal P., Welsch D.J., Mathews W.R. Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo. Anal Biochem 2007, 361:93-101.
14. Verzijl N., DeGroot J., Ben Z.C., Brau-Benjamin O., Maroudas A., Bank R.A., et al. Crosslinking by advanced glycation end products increases the stiffness of the collagen network in human articular cartilage: a possible mechanism through which age is a risk factor for osteoarthritis. Arthritis Rheum 2002, 46:114-123.
15. Eyre D.R., Weis M.A. The Helix-II epitope: a cautionary tale from a cartilage biomarker based on an invalid collagen sequence. Osteoarthritis Cartilage 2009, 17:423-426.
16. Mazieres B., Hucher M., Zaïm M., Garnero P. Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 2007, 66:639-645.
17. Garnero P., Aronstein W.S., Cohen S.B., Conaghan P.G., Cline G.A., Christiansen C., et al. Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. Osteoarthritis Cartilage 2008, 16:660-666.
18. Garnero P., Ayral X., Rousseau J.C., Christgau S., Sandell L.J., Dougados M., et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 2002, 46(10):2613-2624.
19. Cahue S., Sharma L., Dunlop D., Ionescu M., Song J., Lobanok T., et al. The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis. Osteoarthritis Cartilage 2007, 15:819-823.
20. Sharif M., Kirwan J., Charni N., Sandell L.J., Whittles C., Garnero P.A. 5-Yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis - association with disease progression. Rheumatology 2007, 46:938-943.
21. Benito M.J., Veale D.J., FitzGerald O., van den Berg W.B., Bresnihan B. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005, 64:1263-1267.
22. Kong S.Y., Stabler T.V., Criscione L.G., Elliott A.L., Jordan J.M., Kraus V.B. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. Arthritis Rheum 2006, 54:2496-2504.
23. Quintana D.J., Garnero P., Huebner J.L., Charni-Ben Tabassi N., Kraus V.B. PIIANP and HELIXII diurnal variation. Osteoarthritis Cartilage 2008, 16:1192-1195.
24. Andersson M.L., Thorstensson C.A., Roos E.M., Petersson I.F., Heinegard D., Saxne T. Serum levels of cartilage oligomeric matrix protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritis. BMC Musculoskelet Disord 2006, 7:98.
25. Andersson M.L., Petersson I.F., Karlsson K.E., Jonsson E.N., Månsson B., Heinegård D., et al. Diurnal variation in serum levels of cartilage oligomeric matrix protein in patients with knee osteoarthritis or rheumatoid arthritis. Ann Rheum Dis 2006, 65:1490-1494.
26. Gordon C.D., Stabler T.V., Kraus V.B. Variation in osteoarthritis biomarkers from activity not food consumption. Clin Chim Acta 2008, 398:21-26.
27. Georges C., Vigneron H., Ayral X., Listrat V., Ravaud P., Dougados M., et al. Serum biologic markers as predictors of disease progression in osteoarthritis of the knee. Arthritis Rheum 1997, 40:590-591.
28. Jung Y.O., Do J.H., Kang H.J., Yoo S.A., Yoon C.H., Kim H.A., et al. Correlation of sonographic severity with biochemical markers of synovium and cartilage in knee osteoarthritis patients. Clin Exp Rheumatol 2006, 24:253-259.
29. Kumm J., Tamm A., Veske K., Lintrop M., Tamm A. Associations between cartilage oligomeric matrix protein and several articular tissues in early knee joint osteoarthritis. Rheumatology (Oxford) 2006, 45:1308-1309.
30. Zivanovic S., Rackov L.P., Vojvodic D., Vucetic D. Human cartilage glycoprotein 39-biomarker of joint damage in knee osteoarthritis. Int Orthop 2009, 33:1165-1170.
31. Bruyere O., Collette J., Kothari M., Zaim S., White D., Genant H., et al. Osteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study. Ann Rheum Dis 2006, 65:1050-1054.
32. Hunter D.J., LaValley M., Li J., Bauer D.C., Nevitt M., DeGroot J., et al. Biochemical markers of bone turnover and their association with bone marrow lesions. Arthritis Res Ther 2008, 10(4).
33. Raynauld J.P., Martel-Pelletier J., Berthiaume M.J., Beaudoin G., Choquette D., Haraoui B., et al. Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes. Arthritis Res Ther 2006, 8:R21.
34. Garnero P., Peterfy C., Zaim S., Schoenharting M. Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study. Arthritis Rheum 2005, 52:2822-2829.
35. Otterness I.G., Brandt K.D., Le Graverand M.P., Mazzuca S.A. Urinary TIINE concentrations in a randomized controlled trial of doxycycline in knee osteoarthritis: implications of the lack of association between TIINE levels and joint space narrowing. Arthritis Rheum 2007, 56:3644-3649.